New hope for men with early spread prostate cancer: shorter drug course may boost quality of life

NCT ID NCT05404139

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at men whose prostate cancer has spread to a few spots in the body (oligometastatic). It compares standard radiation and hormone therapy alone versus adding the drug abiraterone for 8-9 months. The goal is to see if the extra drug improves quality of life and delays cancer progression. About 132 men will take part, and they will be followed for up to 5 years.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Princess Margaret Cancer Center

    RECRUITING

    Toronto, Ontario, M5G 2M9, Canada

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Sunnybrook Research Institute

    ACTIVE_NOT_RECRUITING

    Toronto, Ontartio, M4N 3M5, Canada